Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SPRC SciSparc
0.880-0.020-2.22%
Trading Session
02/01 14:22 ET
High
0.920
Open
0.920
Turnover
82.89K
Low
0.866
Pre Close
0.900
Volume
93.50K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.Ens
SciSparc to Restructure, Transfer Pharmaceutical Activities to New Subsidiary
SciSparc Announces Corporate Restructuring Plan
SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest TEL AVIV, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC)
Trading Is Mixed After Various Companies Allege Illegal Short Selling
By Will Feuer Trading was mixed amid a growing number of small-cap companies that alleged illegal trading of their stocks on Monday, joining others who have said this month they are investigating all
SciSparc to Address Possible Illegal Short Sales of Its Shares
By Chris Wack SciSparc Ltd. said Monday its board of directors has decided to examine alternative measures to address concerns of illegal short sales of its ordinary shares. The pharmaceutical compa
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of Its Ordinary Shares
The Company is expected to evaluate alternatives to address potential short sales issue TEL AVIV, Israel, Jan. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"),
IIPR, EVGO and BTBT Among Pre Market Losers
SciSparc Obtains Medical Center Approval for Clinical Study of Drug Candidate to Treat Autism Spectrum Disorder in Children
08:30 AM EST, 01/18/2023 (MT Newswires) -- SciSparc (SPRC) said Wednesday that the Soroka University Medical Center in Israel has authorized the company's clinical study of its drug candidate SCI-210
Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results
Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ:CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical st
SciSparc Stock Rises on Getting Approval in Israel to Conduct Trial of SCI-210 for Autism
Company Overview
More
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.
CEO： Mr. Oz Adler
Market： NASDAQ
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet